HETEROCYCLIC COMPOUND FOR USE IN ELECTRONIC DEVICES
申请人:Merck Patent GmbH
公开号:US20210363159A1
公开(公告)日:2021-11-25
The present invention relates to heterocyclic compounds, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
NHC-Catalyzed intramolecular benzoin condensation–oxidation is developed for the expedient synthesis of diverse cyclic 1,2-diketones incorporated in dibenzo-fused seven-membered heterocycles in good to excellent yields, under ambient conditions. The presented carbene-catalyzed transformation appears to proceed through the benzoin intermediate followed by aerobic oxidation.
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R
1
, R
2
, R
3
and R
4
are described in this application, and methods of using said compounds in the treatment of cancer.
The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.
A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11)(R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof.
A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents -NH-; X4 represents a hydrogen atom or the like; R1 represents -C(R11) (R12)- or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).